Revance Therapeutics Inc (RVNC)

[soma2022]

Dew: if your Q42023 revenue estimate of $90M+ is anywhere near that number and revance will explode toward $40 in no time. It took Evolus 4 years to go from $10M/quarter in Jeuveau sales to $46M last quarter which is 15% quarterly growth, taking into acct 2 to 3 quarters of little to no growth due to covid lockdowns.

My Q4 Daxi revenue range is $34 to $38M which is 35 to 50% Q/Q daxi rev growth. 25 to 30% compound quarterly rev growth for Daxi cosmetic next 8 quarters gets Daxi cosmetic to $600M in annual sales run rate by year end 2025, then add in Daxi therapeutic and RHA and we should be at $1B annual sales run rate by end of 2025 at margins in the mid 70s with only slight increase to opex and EPS of $2.50 and a 30x PE gets us to $75/share by late 2025.

If we can eliminate the need for any further secondary raise next 12 months and the shorts will need to cover in a highly disorganized manner that makes all valuation pricing worthless.